Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0044 | 0 | 0.5 |
Schistosoma mansoni | lipoxygenase | 0.0098 | 0.0843 | 0.0843 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.0363 | 0.4959 | 1 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0044 | 0 | 0.5 |
Loa Loa (eye worm) | DOMON domain-containing protein | 0.0069 | 0.0396 | 0.0799 |
Toxoplasma gondii | inositol(myo)-1(or 4)-monophosphatase 2, putative | 0.0044 | 0 | 0.5 |
Echinococcus granulosus | arachidonate 5 lipoxygenase | 0.014 | 0.15 | 0.3025 |
Trypanosoma brucei | inositol-1(or 4)-monophosphatase 1, putative | 0.0044 | 0 | 0.5 |
Trichomonas vaginalis | inositol monophosphatase, putative | 0.0044 | 0 | 0.5 |
Brugia malayi | DOMON domain containing protein | 0.0069 | 0.0396 | 0.0799 |
Onchocerca volvulus | 0.0069 | 0.0396 | 0.5 | |
Wolbachia endosymbiont of Brugia malayi | fructose-1,6-bisphosphatase | 0.0044 | 0 | 0.5 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.0179 | 0.2095 | 0.4225 |
Onchocerca volvulus | 0.0069 | 0.0396 | 0.5 | |
Schistosoma mansoni | lipoxygenase | 0.014 | 0.15 | 0.15 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0044 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0363 | 0.4959 | 1 |
Brugia malayi | DOMON domain containing protein | 0.0069 | 0.0396 | 0.0799 |
Mycobacterium ulcerans | extragenic suppressor protein SuhB | 0.0044 | 0 | 0.5 |
Brugia malayi | DOMON domain containing protein | 0.0069 | 0.0396 | 0.0799 |
Leishmania major | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0044 | 0 | 0.5 |
Echinococcus multilocularis | peptidyl glycine alpha amidating monooxygenase | 0.0363 | 0.4959 | 1 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.0363 | 0.4959 | 1 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0044 | 0 | 0.5 |
Schistosoma mansoni | peptidylglycine monooxygenase | 0.0363 | 0.4959 | 0.4959 |
Schistosoma mansoni | peptidyl-glycine monooxygenase | 0.0363 | 0.4959 | 0.4959 |
Echinococcus granulosus | peptidyl glycine alpha amidating monooxygenase | 0.0363 | 0.4959 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0363 | 0.4959 | 1 |
Entamoeba histolytica | myo-inositol monophosphatase, putative | 0.0044 | 0 | 0.5 |
Loa Loa (eye worm) | DOMON domain-containing protein | 0.0069 | 0.0396 | 0.0799 |
Loa Loa (eye worm) | DOMON domain-containing protein | 0.0069 | 0.0396 | 0.0799 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, N-terminal domain containing protein | 0.0184 | 0.2179 | 0.4395 |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | 0.014 | 0.15 | 0.3025 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.1623 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 7.3753 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.